The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.
News about Johnson & Johnson
J&J thinks it can get more than 10 huge-selling drugs to the market by 2021.
The lawsuit claims the drugmakers misrepresented the dangers of long-term opioid use.
Thank the State Department.
The verdict was the largest so far to arise out of about 2,400 lawsuits.
Lower prices could be on the horizon.
Videos about Johnson & Johnson
Group Worldwide Chairman Sandi Peterson explains
Group worldwide chairman Sandi Peterson explains
According to this Johnson & Johnson exec